Arterra Bioscience Reports Full-Year 2023 Earnings

Arterra Bioscience (BIT:ARBS) Full Year 2023 Results

Key financial results

• Revenue: EUR 4.72 million (down 1.8% compared to 2022).
• Net profit: EUR 1.08 million (down 24% compared to 2022).
• Profit margin: 23% (down from 29% in FY2022). The decrease in margin was primarily due to higher costs.

All numbers shown in the above chart are for the last 12 months (TTM)

Arterra Bioscience shares are up 11% from the previous week.

Risk assessment

You should always think about the risk. For example, we noticed 2 warning signs for Arterra Bioscience you should be aware of this.

Have an opinion on this article? Worried about content? contact with us directly. You can also email us at editorial-team (at) simplywallst.com.

This Simply Wall St article is for general information purposes only. We comment based on historical data and analyst forecasts, using only an unbiased methodology, and our articles are not intended to provide financial advice. It is not a recommendation to buy or sell any stock and does not take into account your objectives or financial situation. Our goal is to provide long-term, focused analysis based on fundamental data. Please note that our analysis may not reflect the latest price-sensitive company announcements or qualitative content. Simply Wall St has no position in any of the stocks mentioned.

Have feedback on this article? Concerned about the content? Contact us directly. You can also send an email to [email protected]